Potassium pill may let kidney patients safely boost blood pressure meds
NCT ID NCT06256991
First seen Jan 05, 2026 · Last updated May 17, 2026 · Updated 18 times
Summary
This study tests whether patiromer, a drug that lowers potassium, allows people with chronic kidney disease to safely increase their dose of a common blood pressure medication (irbesartan). The goal is to see if this reduces protein in the urine and lowers blood pressure, which could slow kidney damage. About 44 adults with moderate-to-severe kidney disease will take patiromer or a placebo for 12 weeks, then switch, while their irbesartan dose is adjusted based on potassium levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Medical Center Groningen
RECRUITINGGroningen, Netherlands
Contact
Conditions
Explore the condition pages connected to this study.